NOTE: This site is for informational purposes only. While we make every effort to keep it up to date, there is no guarantee that information is complete, accurate, comprehensive, or the same for all KP regions. The information on this site should not be interpreted or used as a substitute for professional medical care. Please consult your care provider for any personal health questions or before participating in clinical trials.

Search Results

Tip

Your search for Nephrology | All Regions returned 3 studies.


Active, not yet recruiting Who can join A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease Keywords: Nephrology; VX21-147-301; Kidney Diseases; Urologic Diseases; Study Type: INTERVENTIONAL \| Region: California - Northern
Active, currently enrolling Who can join A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy Keywords: Nephrology; WA41937; Kidney Diseases; Glomerulonephritis,… Study Type: INTERVENTIONAL \| Region: California - Northern
Active, currently enrolling Who can join A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY) Keywords: Nephrology; CA41705; Nephritis; Lupus Nephritis; Kidney Diseases; Urologic… Study Type: INTERVENTIONAL \| Region: California - Northern

Search Results

Saved Studies

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease

A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)